98651-66-2,MFCD00868926
Catalog No.:AA01CBDO

98651-66-2 | Pregna-1,4-diene-3,20-dione,21-chloro-6,9-difluoro-11,17-dihydroxy-16-methyl-, (6a,11b,16b)-

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
99%
1 week  
$138.00   $97.00
- +
5mg
99%
1 week  
$304.00   $213.00
- +
10mg
99%
1 week  
$463.00   $324.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA01CBDO
Chemical Name:
Pregna-1,4-diene-3,20-dione,21-chloro-6,9-difluoro-11,17-dihydroxy-16-methyl-, (6a,11b,16b)-
CAS Number:
98651-66-2
Molecular Formula:
C22H27ClF2O4
Molecular Weight:
428.8972
MDL Number:
MFCD00868926
SMILES:
ClCC(=O)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F
Properties
Computed Properties
 
Complexity:
843  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
9  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0  
Rotatable Bond Count:
2  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
2.7  

Literature

Title: Disseminated porokeratosis of Mibelli: A case report.

Journal: Dermatology online journal 20101215

Title: The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.

Journal: Journal of drugs in dermatology : JDD 20090801

Title: Halobetasol versus clobetasol: a study of potency.

Journal: Indian journal of dermatology, venereology and leprology 20090101

Title: Astrocyte response to Junín virus infection.

Journal: Neuroscience letters 20081107

Title: A degradation product of halobetasol propionate: characterization and structure.

Journal: Steroids 20071001

Title: Vexing vesicles.

Journal: The American journal of medicine 20070701

Title: Sebaceous hyperplasia of the vulva: case report and review of the literature.

Journal: Journal of lower genital tract disease 20060101

Title: Ultrapotent topical corticosteroid treatment of hemangiomas of infancy.

Journal: Journal of the American Academy of Dermatology 20050201

Title: Topical halobetasol propionate in the treatment of plaque psoriasis: a review.

Journal: American journal of clinical dermatology 20050101

Title: Nevoid hyperkeratosis of the nipple and/or areola: a report of two cases and a review of the literature.

Journal: International journal of dermatology 20021101

Title: Vitamin D and topical therapy.

Journal: Cutis 20021101

Title: Spectrophotometric determination of clobetasol propionate, halobetasol propionate, quinagolide hydrochloride, through charge transfer complexation.

Journal: Journal of pharmaceutical and biomedical analysis 20020301

Title: Treating psoriasis in primary care settings. Preserving quality of life is a primary--and possible--goal.

Journal: Advance for nurse practitioners 20011201

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:98651-66-2 Molecular Formula|98651-66-2 MDL|98651-66-2 SMILES|98651-66-2 Pregna-1,4-diene-3,20-dione,21-chloro-6,9-difluoro-11,17-dihydroxy-16-methyl-, (6a,11b,16b)-
Catalog No.: AA01CBDO
98651-66-2,MFCD00868926
98651-66-2 | Pregna-1,4-diene-3,20-dione,21-chloro-6,9-difluoro-11,17-dihydroxy-16-methyl-, (6a,11b,16b)-
Pack Size: 1mg
Purity: 99%
1 week
$138.00 $97.00
Pack Size: 5mg
Purity: 99%
1 week
$304.00 $213.00
Pack Size: 10mg
Purity: 99%
1 week
$463.00 $324.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA01CBDO
Chemical Name: Pregna-1,4-diene-3,20-dione,21-chloro-6,9-difluoro-11,17-dihydroxy-16-methyl-, (6a,11b,16b)-
CAS Number: 98651-66-2
Molecular Formula: C22H27ClF2O4
Molecular Weight: 428.8972
MDL Number: MFCD00868926
SMILES: ClCC(=O)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F
Properties
Complexity: 843  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 9  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 29  
Hydrogen Bond Acceptor Count: 6  
Hydrogen Bond Donor Count: 2  
Isotope Atom Count: 0  
Rotatable Bond Count: 2  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 2.7  
Literature fold

Title: Disseminated porokeratosis of Mibelli: A case report.

Journal: Dermatology online journal20101215

Title: The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.

Journal: Journal of drugs in dermatology : JDD20090801

Title: Halobetasol versus clobetasol: a study of potency.

Journal: Indian journal of dermatology, venereology and leprology20090101

Title: Astrocyte response to Junín virus infection.

Journal: Neuroscience letters20081107

Title: A degradation product of halobetasol propionate: characterization and structure.

Journal: Steroids20071001

Title: Vexing vesicles.

Journal: The American journal of medicine20070701

Title: Sebaceous hyperplasia of the vulva: case report and review of the literature.

Journal: Journal of lower genital tract disease20060101

Title: Ultrapotent topical corticosteroid treatment of hemangiomas of infancy.

Journal: Journal of the American Academy of Dermatology20050201

Title: Topical halobetasol propionate in the treatment of plaque psoriasis: a review.

Journal: American journal of clinical dermatology20050101

Title: Nevoid hyperkeratosis of the nipple and/or areola: a report of two cases and a review of the literature.

Journal: International journal of dermatology20021101

Title: Vitamin D and topical therapy.

Journal: Cutis20021101

Title: Spectrophotometric determination of clobetasol propionate, halobetasol propionate, quinagolide hydrochloride, through charge transfer complexation.

Journal: Journal of pharmaceutical and biomedical analysis20020301

Title: Treating psoriasis in primary care settings. Preserving quality of life is a primary--and possible--goal.

Journal: Advance for nurse practitioners20011201

Building Blocks More >
83014-68-0
83014-68-0
Alphaxalone-d5
AA01CBGV
1185239-59-1
1185239-59-1
trans,trans-Muconic Acid-d4
AA01CBJV
67308-21-8
67308-21-8
5-Thia-1-azabicyclo[4.2.0]octane-2-carboxylic acid,7-[(aminophenylacetyl)amino]-3-methylene-8-oxo-, [6R-[6a,7b(R*)]]-
AA01CBNQ
49614-72-4
49614-72-4
Thiazolium,3-[(4-amino-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methyl-, chloride,monohydrochloride
AA01CBRN
828-00-2
828-00-2
1,3-Dioxan-4-ol, 2,6-dimethyl-, acetate
AA01CBUL | MFCD00069040
864445-54-5
864445-54-5
JWH 203
AA01CBXT | MFCD19440913
1485692-21-4
1485692-21-4
Dolutegravir O-β-D-Glucuronide
AA01CC1E
185502-39-0
185502-39-0
Cyclohexanol, 2-(aminomethyl)-1-(3-methoxyphenyl)-, (1R,2R)-rel-
AA01CC4A | MFCD04039437
1936247-99-2
1936247-99-2
2-Bromo-2-chloro-1,1-ethanediol
AA01CC7Q
1185012-24-1
1185012-24-1
Ractopamine-d6 Ketone Hydrochloride
AA01CCAY | MFCD28899401
Submit
© 2017 AA BLOCKS, INC. All rights reserved.